American tegumentary leishmaniasis: Cytokines and nitric oxide in active disease and after clinical cure, with or without chemotherapy

Scandinavian Journal of Immunology

Volumn 76, Issue 2, 2012, Pages 175-180

  Souza, M A ^a   Castro, M C A B ^a   Oliveira, A P ^a   Almeida, A F ^a   Reis, L C ^b   Silva, C J ^c   Brito, M E F ^a   Pereira, V R A ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Núcleo de Vigilância em Saúde e Ambiente do Município de Moreno   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; IMMUNE RESPONSE; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELLS, CULTURED; CYTOKINES; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; NITRIC OXIDE; YOUNG ADULT;

EID: 84864304971     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2012.02717.x     Document Type: Article

References (29)

1. Gontijo B, Carvalho MLR. Leishmanose Tegumentar Americana. Rev Soc Bras Med Trop 2003;36:71-80.
2. Basano SA, Camargo LMA. Leishmaniose Tegumentar Americana: histórico, epidemiologia e perspectivas de controle. Rev Bras Epidemiol 2004;7:328-37.
3. Rogers KA, DeKrey GK, Mbow ML, Gillespie RD, Brodskyn CI, Titus RG. Type 1 and type 2 responses to Leishmania major. FEMS Microbiol Lett 2002;209:1-7.
4. Reis LC, Brito MEF, Souza MA, Pereira VRA. Mecanismos imunológicos na resposta celular e humoral na leishmaniose tegumentar americana. Rev Patol Trop 2006;35:103-15.
5. Coutinho SG, Oliveira MP, Da Cruz AM et al. T-cell responsiveness of american cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. Exp Parasitol 1996;84:144-55.
6. Von Stebut E. Cutaneous Leishmania infection: progress in pathogenesis research and experimental therapy. Exp Dermatol 2007;16:340-6.
7. Bacellar O, Lessa H, Schriefer A et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 2002;70:6734-40.
8. Bacellar O, Faria D, Nascimento M et al. Interleukin 17 production among patients with American Cutaneous Leishmaniasis. J Infect Dis 2009;200:75-8.
9. H17 cells. Nature 2008;453:1051-7.
10. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485-517.
11. Pitta MRG, Romano A, Cabantous S. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest 2009;119:2379-87.
12. Antonelli LRV, Dutra WO, Almeida RP, Bacellar O, Gollob KJ. Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mechanisms for immunoregulation. Clin Exp Immunol 2004;136:341-8.
13. Toledo VPCP, Mayrink W, Gollob KJ et al. Immunochemotherapy in american cutaneous leishmaniasis: immunological aspects before and after treatment. Mem Inst Oswaldo Cruz 2001;96:89-98.
14. Da Cruz AM, Bittar R, Mattos M et al. T-cell mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clin Diagn Lab Immunol 2002;9:251-6.
15. Reis LC, Brito MEF, Souza MA et al. Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment. J Clin Lab Anal 2009;23:63-9.
16. Carvalho EM, Correia-Filho D, Bacellar O, Almeida RP, Lessa H, Rocha H. Characterization of the immune response in subjects with self healing cutaneous leishmaniasis. Am J Trop Med Hyg 1995;53:273-7.
17. Gomes-Silva A, Bittar RC, Dos Santos Nogueira R et al. Can interferon-γ and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection? Clin Exp Immunol 2007;149:440-4.
18. Brito ME, Mendonça MG, Gomes YM, Jardim ML, Abath FG. Dynamics of the antibody response in patients with therapeutic or spontaneous cure of american cutaneous leishmaniasis. Trans R Soc Trop Med Hyg, 2001;95:203-6.
19. Coutinho SG, Da Cruz AM, Bertho AL, Santiago MA, De Luca P. Immunologic patterns associated with cure in human american cutaneous leishmaniasis. Braz J Med Biol Res 1998;31:139-42.
20. Kocyigit A, Gur S, Gurel MS, Bulut V, Ulukanligil M. Antimonial therapy induces circulating proinflammatory cytokines in patients with cutaneous leishmaniasis. Infect Immun 2002;70:6589-91.
21. Muniz-Junqueira MI, Paula-Coelho VN. Meglumine antimonate directly increases phagocytosis, superoxide anion and TNF-α production, but only via TNF-α it indirectly increases nitric oxide production by phagocytes of healthy individuals, in vitro. Int Immunopharmacol, 2008;8:1633-8.
22. Gorak PM, Engwerda CR, Kaye PM. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol 1998;28:687-95.
23. Herwaldt BL. Leishmaniasis. Lancet 1999;354:1191-9.
24. Kane MM, Mosser DM. Leishmania parasites and their plays to disrupt macrophage activation. Curr Opin Hematol 2000;7:26-31.
25. Gollob KJ, Antonelli LRV, Faria DR, Keseen TSL, Dutra WO. Immunoregulatory mechanisms and CD4-CD8- (double negative) T cell subpopulations in human cutaneous leishmaniasis: a balancing act between protection and pathology. Int Immunopharmacol 2008;8:1338-43.
26. Matsuzaki G, Umemura M. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol 2007;51:1139-47.
27. Niedbala W, Alves-Filho JC, Fukada SY et al. Regulation of type 17 helper T-cell function by nitric oxide during inflammation. Proc Natl Acad Sci U S A 2011;108:9220-5.
28. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008;28:454-67.
29. Sonnenberg GF, Nair MG, Kirn TJ, Zaph C, Fouser LA, Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010;207:1293-304.